argenx SE
(NASDAQ : ARGX)

( )
ARGX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 2.25%93.515.5%$179.67m
VRXValeant Pharmaceuticals International, Inc. 0.13%30.3014.1%$178.29m
ICLRICON plc 4.47%205.204.2%$131.92m
CTLTCatalent, Inc. 1.02%111.032.1%$128.45m
GWPHGW Pharmaceuticals Plc 0.21%218.816.1%$124.34m
BHCBausch Health Cos., Inc. 0.13%30.300.0%$108.60m
UTHRUnited Therapeutics Corp. -0.55%201.6714.1%$97.68m
JAZZJazz Pharmaceuticals Plc 1.21%168.392.3%$90.22m
SAVACassava Sciences, Inc. -1.63%35.090.0%$67.46m
ARGXargenx SE 1.72%277.470.0%$51.25m
PRGOPerrigo Co. Plc 1.94%41.176.9%$37.55m
SAGESAGE Therapeutics, Inc. -0.23%75.507.6%$37.53m
AMRNAmarin Corp. Plc -1.96%5.011.5%$29.35m
PCRXPacira Biosciences, Inc. -4.45%66.349.9%$27.57m
ICPTIntercept Pharmaceuticals, Inc. -4.02%20.5516.8%$22.11m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.